Safety and Efficacy of DIDALA Monotherapy in Patients With Type 2 Diabetes Compared With Metformin.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.

Also called NCT05760456

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 140 participants (planned count) (from the registry)
Sponsor
Centre of Clinical Pharmacology, Hanoi Medical University (from the registry)
Registry
  • NCT NCT05760456
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Vietnam (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05760456. Randomized; no masking; primary purpose treatment. Start 2023-03-15 (anticipated); primary completion 2024-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of DIDALA Monotherapy in Patients With Type 2 Diabetes Compared With Metformin.
Intervention (Drug)
DIDALA hard capsules
Intervention (Drug)
Metformin
Lead sponsor
Centre of Clinical Pharmacology, Hanoi Medical University (class: other)

Record details

Record id
cardio:ct-nct05760456
Content hash
39ce1e5a72559a6b498a5f449eb66fc89b35a53cd44bb2baa1e21e0da53274cb